Wednesday , October 18 2017
Home / 2015 / November

Monthly Archives: November 2015

More than a GPO – Premier’s efforts in transforming healthcare

While Premier, Inc. is widely known for operating one of the nation’s largest group purchasing organizations (GPOs) by volume, many may be unaware of the additional suite of valuable services that the company provides to its members to improve the health of communities. Premier is a leading healthcare performance improvement …

Read More »

SkylineDx Receives CE-IVD Mark for its Gene Signature-Based Test for Multiple Myeloma

ROTTERDAM, Netherlands and LAGUNA HILLS, Calif., Nov. 25, 2015 /PRNewswire/ — SkylineDx, today announced they have received CE-IVD registration from the European Competent Authority (Ministry of Health) for the MMprofiler™, the company’s prognostic test to determine the level of risk of a patient with multiple myeloma (MM). SkylineDx is an emerging …

Read More »

FDA Approves BMS’ Opdivo for Treatment of Renal Cell Carcinoma

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab) injection, for intravenous use, for the treatment of patients with advanced renal cell carcinoma (RCC) who have received prior anti-angiogenic therapy.1 Today’s announcement marks the approval of the first and …

Read More »

FDA Approves Lilly’s Portrazza for Patients with Squamous NSCLC

INDIANAPOLIS, Nov. 24, 2015 /PRNewswire/ —  Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved Portrazza™ (necitumumab injection for intravenous use, 800 mg/50 mL), in combination with gemcitabine and cisplatin, as the first biologic for the first-line treatment of people with …

Read More »

HIV Treatment Choices Expand

More than 1.2 million Americans live with HIV infection and one in eight has not yet been diagnosed, according to the Centers for Disease Control and Prevention. Despite public health initiatives, each year approximately 50,000 more Americans are infected with this virus. There is now a new medication available to …

Read More »

Roche’s Melanoma Drug Performs Well in Early-Stage Study

Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data from the pivotal coBRIM study, which showed that Cotellic (cobimetinib) in combination with Zelboraf (vemurafenib) helped people with BRAF V600E and V600K mutation-positive unresectable or metastatic melanoma live significantly longer (overall survival; OS) than with Zelboraf alone.1 Cotellic plus Zelboraf reduced …

Read More »

CytRx’ Aldoxorubicin Continues to Demonstrate Positive Clinical Activity in Mid-Stage Brain Cancer Trial

LOS ANGELES, Nov. 23, 2015 /PRNewswire/ — CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has achieved its target enrollment of 28 patients with unresectable glioblastoma multiforme (GBM), a deadly form of brain cancer, in its Phase 2 trial with aldoxorubicin. …

Read More »

Novartis’ Skin Cancer Drug Combo Receives Full FDA Approval

EAST HANOVER, N.J., Nov. 20, 2015 /PRNewswire/ — Novartis today announced that the US Food and Drug Administration (FDA) has granted regular approval for the combination of Tafinlar® (dabrafenib) + Mekinist®(trametinib) for the treatment of patients with BRAF V600E/K mutation-positive unresectable or metastatic melanoma as detected by an FDA-approved test. …

Read More »